Information Provided By: 
Fly News Breaks for December 11, 2018
GWPH
Dec 11, 2018 | 16:07 EDT
Oppenheimer analyst Esther Rajavelu started GW Pharmaceuticals with a Perform rating and $142 price target. With Epidiolex, a first-in-class phytocannabidiol medication for the treatment of certain types of seizures, the company is well positioned for both revenue growth and pipeline expansion, Rajavelu tells investors in a research note. However, the analyst believes GW's positive drivers are fairly reflected in the stock at current levels.
News For GWPH From the Last 2 Days
There are no results for your query GWPH
